Cathie Wood's ARK Invest carried out a series of trades this week, scaling back several healthcare holdings while adding to positions in Freenome, Scribe Therapeutics, and Rocket Lab as the space company's share price declined.

The firm publishes its fund trades each day, giving outside observers a running view of its positioning across strategies such as the ARK Genomic Revolution ETF (ARKG), through which several of this week's healthcare trades were executed.

According to the firm's published daily trade disclosures for Friday, October 16, 2026, the largest transaction of the day was the sale of 670,746 shares of Personalised, Inc. through the ARKG ETF, valued at $10,684,983. The sale extends a trend from earlier in the week, when ARK sold large blocks of Personalised stock on several days as the fund continued to reduce its position in the company.

ARK Adds to Freenome and Scribe Therapeutics

On the buying side, ARK acquired 254,668 shares of Freenome, Inc. (FRNM), a developer of blood-based cancer detection tests, through ARKG in a purchase worth $3,129,869, adding to the fund's recent accumulation of Freenome shares.

ARK also bought 29,416 shares of Scribe Therapeutics Inc., a gene-editing company, for a total of $609,499, building on smaller purchases of the stock made earlier in the week.

At the same time, the fund sold 59,477 shares of CareDx, Inc., which specializes in diagnostics for transplant patients, through ARKG in a transaction totaling $3,965,926. ARK has sold CareDx shares steadily over the past week.

Shares of the companies involved moved lower after the trades were reported. Freenome fell 4.40%, Scribe Therapeutics declined 3.09%, CareDx dropped 4.00%, and Personalised slipped 1.76%. The ARKG ETF itself was down 5.16%.

ARK Buys Rocket Lab After Sell-Off

ARK also made a separate purchase in the space sector. On Thursday, ARK funds bought 168,633 shares of Rocket Lab valued at approximately $9.3 million. The purchase came as Rocket Lab shares fell nearly 7%, extending a year-to-date decline of about 21%. The stock fell another 7.98% in its latest session.

Investor attention has centered on Neutron, the company's planned medium-lift rocket, which would sit above its operational small-lift Electron in payload capacity. Rocket Lab has pushed the vehicle's first launch to 2027 after production issues required additional work. The delay pushes back a possible new source of revenue, while building the rocket adds to spending. Rocket Lab reported negative free cash flow of $110 million in the second quarter.

The company's current business offers some support. Its backlog reached $2.36 billion at the end of June, up 137% from a year earlier, and Rocket Lab also holds an agreement covering 20 Electron launches, adding to future launch demand. Neutron's schedule and development costs remain key factors for investors, and upcoming quarterly updates on cash flow and backlog will provide fresh data points as the 2027 launch target approaches. The firm's daily disclosures, meanwhile, will show whether this week's pattern of selling Personalised and CareDx while buying Freenome, Scribe Ther, and Rocket Lab continues.

Source: CoinCentral